Power and sample size considerations in clinical trials with competing risk endpoints.
In clinical trials with a time-to-event endpoint, subjects are often at risk for events other than the one of interest. When the occurrence of one type of event precludes observation of any later events or alters the probably of subsequent events, the situation is one of competing risks. During the planning stage of a clinical trial with competing risks, it is important to take all possible events into account. This paper gives expressions for the power and sample size for competing risks based on a flexible parametric Weibull model. Nonuniform accrual to the study is considered and an allocation ratio other than one may be used. Results are also provided for the case where two or more of the competing risks are of primary interest.
Maki
Ellen
E
Analytica Statistical Consulting Inc., 19 Broadleaf Road, Toronto, ON, Canada. ellen.maki@sympatico.ca
D002986:Clinical Trials as Topic / Q000379:methods*; D003627:Data Interpretation, Statistical; D023381:Endpoint Determination; D006801:Humans; D012107:Research Design; D012306:Risk; D018401:Sample Size